Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotronik Starts First ICD Study Designed To Measure Sex-Specific Outcomes

Executive Summary

BIO-LIBRA will study Biotronik ICDs and CRT-D devices in about 1,000 patients with non-ischemic cardiomyopathy. The investigators expect at least 40% of the subjects in BIO-LIBRA to be women.

You may also be interested in...

Women Benefit More From CRT-D, Likely Undertreated, CDRH Finds

Women with heart failure, a left bundle block branch and heart-rhythm activity that typically does not qualify them for a top-level guideline recommendation to receive cardiac resynchronization therapy plus defibrillator clearly benefit from the therapy, while men do not, suggesting underuse, according to a study conducted by FDA device center researchers.

Congress Leans On FDA, NIH To Put More Women In Clinical Trials

There was a significant focus on putting more women in clinical trials on Capitol Hill on April 30, when 14 female Senators sent a letter to FDA, calling for an action plan to spur greater subgroup, especially female, participation in clinical trials, while a group of 10 Democrats asked GAO to examine what NIH is doing to meet the same goals.

Clinical Trial Guidance Seeks To Improve Sex-Based Data

Top goal of recent draft guidance is to increase the proportion of women participating in device trials. The document also emphasizes the types of analyses FDA will expect from device manufacturers to make the most of sex-specific data.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts